

Drug Enforcement Administration

[Docket No. DEA-742]

Importer of Controlled Substances Application: Lyndra Therapeutics

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

SUMMARY: Lyndra Therapeutics has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplemental Information listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before [INSERT DATE 30 DAYS AFTER DATE OF PUBLICATION IN THE FEDERAL REGISTER]. Such persons may also file a written request for a hearing on the application on or before [INSERT DATE 30 DAYS AFTER DATE OF PUBLICATION IN THE FEDERAL REGISTER].

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration,
Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for a hearing must be sent to: Drug Enforcement
Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152.
All requests for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug
Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this is notice that on October 22, 2020, Lyndra Therapeutics, 65 Grove Street, Suite 301,

Watertown, Massachusetts 02472, applied to be registered as an importer of the following

basic class(es) of controlled substance(s):

Drug Code Schedule Controlled Substance II Methadone 9250

The company plans to develop the formulation and process, and then manufacture the

finished oral dosage form for use in preclinical and human clinical trials under a research

grant from National Institute on Drug Abuse. No other activity for these drug codes is

authorized for this registration.

Approval of permit applications will occur only when the registrant's business activity is

consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend

to the import of Food and Drug Administration-approved or non-approved finished dosage

forms for commercial sale.

William T. McDermott,

Assistant Administrator.

[FR Doc. 2020-26175 Filed: 11/25/2020 8:45 am; Publication Date: 11/27/2020]